There were 372 press releases posted in the last 24 hours and 440,597 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
AIMイムノテック (AIM ImmunoTech)、新型コロナウイルス感染症の罹患後症状の治療薬としてAmpligen®を評価する第2相試験で最初の被験者を登録、投薬

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image